logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On November 12th, PW MEDTECH (01358) spent 1.034 million Hong Kong dollars to repurchase 1 million shares.

date
20:02 12/11/2024
avatar
GMT Eight
PwC Holdings Limited (01358) announced on November 12, 2024 that it will spend HK$103.4 million to repurchase its shares.
PW MEDTECH (01358) announced that on November 12, 2024, it will spend 1.034 million Hong Kong dollars to repurchase 1 million shares at a repurchase price of 1.03-1.04 Hong Kong dollars per share.
Related Articles
HK Stock
STANCHART (02888) spent 9.8582 million pounds to repurchase 549,000 shares on January 9th.
HK Stock
HAITONG UT (01905) plans to issue corporate bonds not exceeding 1 billion yuan.
China Stock
Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) submitted an application for the issuance of H shares, and the materials have been accepted by the China Securities Regulatory Commission.
STANCHART (02888) spent 9.8582 million pounds to repurchase 549,000 shares on January 9th.
HK Stock
HAITONG UT (01905) plans to issue corporate bonds not exceeding 1 billion yuan.
HK Stock
Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) submitted an application for the issuance of H shares, and the materials have been accepted by the China Securities Regulatory Commission.
China Stock
RECOMMEND
Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
icon
10/01/2026
Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
icon
10/01/2026
“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
icon
10/01/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.